Minimal residual disease analysis in childhood mature B-cell leukaemia/lymphoma treated with AIEOP LNH-97 protocol with/without anti-CD20 administration

被引：8

作者：

Mussolin, Lara ^{[1
,2
]}

Lovisa, Federica ^{[1
,2
]}

Gallingani, Ilaria ^{[1
]}

Cavallaro, Elena ^{[1
]}

Carraro, Elisa ^{[1
]}

Damanti, Carlotta C. ^{[1
]}

Vinti, Luciana ^{[3
]}

Sala, Alessandra ^{[4
]}

Micalizzi, Concetta ^{[5
]}

Santoro, Nicola ^{[6
]}

Piglione, Matilde ^{[7
]}

Cellini, Monica ^{[8
]}

Buffardi, Salvatore ^{[9
]}

Buldini, Barbara ^{[1
]}

D'Amore, Emanuele S. G. ^{[10
]}

Biffi, Alessandra ^{[1
,2
,11
]}

Pillon, Marta ^{[1
]}

机构：

[1] Univ Padua, Div Pediat Hematol Oncol & Stem Cell Transplant, Dept Women & Child Hlth, Padua, Italy

[2] Ist Ric Pediat Citta Speranza, Padua, Italy

[3] Bambino Gesu Pediat Hosp, Dept Pediat Hematooncol, Rome, Italy

[4] Univ Milano Bicocca, Dept Paediat, Fdn MBBM, Azienda Osped S Gerardo, Monza, Italy

[5] IRCCS Ist Giannina Gaslini, Dept Paediat Haematooncol, Genoa, Italy

[6] Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol, Bari, Italy

[7] Univ Hosp Citta Salute & Sci Torino, Dept Paediat, Paediat Haematol, Turin, Italy

[8] Policlin Hosp, Div Paediat Oncol Haematol, Modena, Italy

[9] Santobono Pausilipon Childrens Hosp, Dept Paediat Haematooncol, Naples, Italy

[10] San Bortolo Hosp, Dept Pathol, Vicenza, Italy

[11] Dana Farber Boston Childrens Canc & Blood Disorde, Gene Therapy Program, Boston, MA USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 189卷 / 03期

关键词：

B-cell acute leukaemia; Burkitt; AIEOP LNH-97; anti-CD20; paediatric; minimal residual disease; NON-HODGKIN-LYMPHOMA; ACUTE-LYMPHOBLASTIC-LEUKEMIA; CHILDREN; ADOLESCENTS; RITUXIMAB; BURKITT; CHEMOTHERAPY; LYMPHOMA/LEUKAEMIA; INTERMEDIATE; THERAPY;

D O I：

10.1111/bjh.16531

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E108 / E111

页数：4

共 32 条

[31] Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma
Lunning, Matthew A.
Vose, Julie M.
Schreeder, Marshall T.
Fowler, Nathan
Nastoupil, Loretta J.
Siddiqi, Tanya
Blumel, Susan
Pauli, Emily K.
Cutter, Kathy
Tse, Warner
Miskin, Hari P.
Sportelli, Peter
Weiss, Michael S.
Vakkalanka, Swaroop
Viswanadha, Srikant
O'Brien, Susan
BLOOD, 2014, 124 (21)
[32] Randomised Intergroup Trial of First line Treatment for young Low-Risk Patients (<61 years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL) with a CHOP-like Regimen with or without the Anti-CD20 Antibody Rituximab-6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group
Pfreundschuh, Michael
Kuhnt, Evelyn
Truemper, Lorenz
Osterborg, Anders
Trneny, Marek
Shepherd, Lois
Gill, Devinder S.
Walewski, Jan
Pettengell, Ruth
Jaeger, Ulrich
Zinzani, Pier Luigi
Shpilberg, Ofer
Kvaloy, Stein
Hansen, Mads
Stahel, Rolf
Milpied, Noel
Lopez-Guillermo, Armando
Grass, Sandra
Murawski, Niels
Poeschel, Viola
Loeffler, Markus
BLOOD, 2010, 116 (21) : 55 - 55

← 1 2 3 4 →